Viaskin® Technology

Our technology platform called Viaskin®, is based on an electrostatic patch, which administers the allergen directly on the skin.

A novel approach to immunotherapy

Once administered, the allergen is concentrated in the superficial layers of the skin, where it activates the immune system by specifically targeting antigen-presenting cells without passage of the antigen into the bloodstream.
DBV calls this novel approach to immunotherapy as epicutaneous immunotherapy, or EPIT®.
DBV Technologies believes EPIT® has the potential to provide all of the intended benefits of a disease-modifying treatment in allergy, while avoiding severe or life-threatening allergic reactions. 

See also

Viaskin® Peanut

Viaskin® Milk

Viaskin® HDM